# A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）

> **NCT05357651** · PHASE1 · RECRUITING · sponsor: **L & L Bio Co., Ltd., Ningbo, China** · enrollment: 100 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** LB1410

## Key facts

- **NCT ID:** NCT05357651
- **Lead sponsor:** L & L Bio Co., Ltd., Ningbo, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-12
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357651, "A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05357651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*